PREVENTion With Sglt-2 Inhibition of Acute Kidney Injury in Intensive Care

NCT ID: NCT05468203

Last Updated: 2025-09-16

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE3
• Total Enrollment: 3000 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-11-29
• Study Completion Date: 2027-03-01

Brief Summary

Background Acute Kidney Injury (AKI) is a potentially life-threatening condition caused by unsafe levels of fluid and waste products accumulating in the body. Often, patients with AKI need treatment with an artificial kidney (called renal replacement therapy or dialysis) to do the work of their kidneys and remove these dangerous levels of fluid and waste from the body. If left untreated, AKI can become a chronic (long-term) condition that may require treatment for life.

Dapagliflozin is a medication used to treat patients with diabetes, heart disease and long-term (chronic) kidney disease. Recently, Dapagliflozin has been shown to slow the progression of other kidney related complications, however this has not yet been studied in critically ill patients.

Aim To determine if giving Dapagliflozin (one tablet a day) compared to placebo (a tablet that looks identical but has no active ingredients), decreases injury to the kidneys in patients admitted to the Intensive Care Unit.

Design This study will enrol 3000 patients from 45-50 hospitals worldwide. It is a 'randomised controlled trial' meaning patients will be randomly assigned (like tossing a coin) by a computer to receive either Dapagliflozin or placebo for a maximum of 30 days whilst in the ICU. The study is also a 'double blinded trial' meaning that neither the doctor, the intensive care staff or the patient will know which study treatment they are receiving.

Detailed Description

Acute kidney injury (AKI) is an increasingly common complication of hospitalisation globally, and a major driver of poor patient outcomes, including higher mortality and reduced quality of life. While numerous studies, including several led by investigators in this grant team, have tested treatments to reduce the impact of AKI, none have been shown to improve outcomes. The absence of any proven therapy highlights a critical unmet need.

A novel class of medicines, inhibitors of the sodium-glucose co-transporter II (SGLT-2 inhibitors), have been shown in recent years to have dramatic effects upon cardiovascular and renal outcomes in patients with heart failure at high risk for renal failure. The evidence suggests that these drugs might prevent AKI from occurring, but this has not been intentionally tested in adequately powered trials. A recently published randomised controlled trial evaluated the use of these drugs in acutely unwell COVID-19 patients and did not raise any safety concern in this acute setting. The trial also showed a numerically lower rate of AKI in those that received the SGLT-2 inhibitor dapagliflozin compared to placebo, but the trial was not sufficiently powered for this outcome.

The PREVENTion with Sglt2 inhibition of Acute Kidney Injury in intensive care (PREVENTS-AKI) trial, will test the effect of dapagliflozin versus placebo upon patients' risk of developing severe AKI in a population admitted to intensive care. This global trial will test the most promising treatment for mitigating the increased risk of AKI. The results will provide the first definitive insight into the prevention of AKI with these agents and will shape global clinical practice in an area where treatments are profoundly lacking.

Conditions

Acute Kidney Injury

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: QUADRUPLE

Study Groups

Dapagliflozin

Dapaliflozin 10mg tablet administered once daily while in ICU for up to 30 days

Group Type: EXPERIMENTAL

Dapagliflozin 10mg Tab

Intervention Type: DRUG

Patients will be randomly assigned to receive either dapagliflozin 10 mg or placebo daily while in ICU for up to 30 days

Matched Placebo

Matched placebo tablet administered once daily while in ICU for up to 30 days

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Patients will be randomly assigned to receive either dapagliflozin 10 mg or placebo daily while in ICU for up to 30 days

Interventions

Dapagliflozin 10mg Tab

Patients will be randomly assigned to receive either dapagliflozin 10 mg or placebo daily while in ICU for up to 30 days

Intervention Type: DRUG

Placebo

Patients will be randomly assigned to receive either dapagliflozin 10 mg or placebo daily while in ICU for up to 30 days

Intervention Type: DRUG

Other Intervention Names

SGLT2 inhibitor

Eligibility Criteria

Inclusion Criteria

• Age 18 years or more
• Admitted to ICU within the last 7 days
• Expected to be in the ICU the day after tomorrow
• An arterial or central venous catheter is in situ, or placement is planned for routine management
• Able to receive study treatment orally or via enteral route
• At least one of the following risk factors for AKI:

• Required fluid resuscitation, defined as a bolus of fluid prescribed to be given over ≤1 hour to increase or maintain intravascular volume that is in addition to maintenance fluids
• Being treated with continuous vasopressors or inotropes to maintain a systolic blood pressure > 90mmHg, or mean arterial blood pressure > 60mmHg or a MAP target set by the treating clinician for maintaining perfusion
• At least one of the following pre-morbid risk factors:

• Treatment for high blood pressure
• Treatment for type 2 diabetes (minimum diet therapy)
• Atherosclerotic cardiovascular disease
• History of heart failure
• Impaired renal function, defined as an eGFR between 20 - 60 mL/min/1.73m2
• Estimated BMI 30 kg/m2 or more
• Age 60 years or more

• History of type 1 diabetes mellitus or diabetic ketoacidosis
• COVID-19 infection as the reason for ICU admission
• Requiring renal replacement therapy for intoxication
• eGFR less than 20 mL/min/1.73m2
• Known hypersensitivity to any SGLT-2 inhibitor e.g. dapagliflozin, canagliflozin, empagliflozin, ertugliflozin
• Solid organ transplantation within the last 12 months
• Likely to be transferred to another hospital in the next 3 days
• Known or suspected pregnancy
• Death is deemed imminent or inevitable
• Life expectancy is estimated to be less than 90 days
• Patient or the treating clinician declines to participate
• Enrolled in another interventional trial for which co-enrolment is not approved
• Patient has previously been enrolled in the PREVENTS-AKI Study

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University Medical Center Groningen

OTHER

Sponsor Role: collaborator

Australian and New Zealand Intensive Care Society Clinical Trials Group

NETWORK

Sponsor Role: collaborator

The George Institute

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Martin P Gallagher, MBBS, FRACP

Role: STUDY_DIRECTOR

The George Institute

Locations

Grampians Health

Ballarat, Victoria, Australia

Site Status: NOT_YET_RECRUITING

Austin Health

Heidelberg, Victoria, Australia

Site Status: RECRUITING

Countries

Australia

Central Contacts

Sarah Coggan, BSc, MPH

Role: CONTACT

scoggan@georgeinstitute.org.au

02 9993 4566

Sharon Micallef, BN

Role: CONTACT

smicallef@georgeinstitute.org.au

Facility Contacts

Khaled El-Khawas, Dr

Role: primary

Rinaldo Bellomo, Prof

Role: primary

Other Identifiers

GI-RM-7738

Identifier Type: -

Identifier Source: org_study_id